Platforms & Modalities

Platforms & Modalities

Sophia CDMO supports a broad range of biologic platforms with phase-appropriate development, analytical, and manufacturing capabilities. Our teams are structured to bring platform experience where it helps (speed and predictability) while maintaining the flexibility required for novel constructs and challenging molecules. We partner with sponsors from early feasibility through clinical supply and commercial readiness, aligning the CMC strategy to your product’s mechanism, formulation needs, and regulatory pathway.

Biologic Platforms We Support

Monoclonal Antibodies (mAbs)

Sophia CDMO provides end-to-end support for monoclonal antibody programs, leveraging established development approaches to accelerate early progress while maintaining a clear path to scalability and control.

Typical program support includes:

  • Upstream and downstream process development designed for robustness and consistent product quality
  • Analytical method development and qualification aligned to stage
  • Impurity clearance strategy development (process-related and product-related)
  • Stability programs and specifications strategy support
  • Tech transfer and GMP manufacturing support for clinical supply (and readiness planning for later phases)

Common objectives we help sponsors achieve:

  • Rapid move from candidate selection into a scalable process
  • Early understanding of CQAs and attributes impacting efficacy and safety
  • A control strategy that supports comparability across scale and site changes

Antibody-Based Therapeutics

For antibody-derived formats, Sophia CDMO supports programs requiring deeper characterization and careful control of heterogeneity.

Examples include:

  • Antibody fragments (e.g., Fab, scFv—where applicable)
  • Fc-engineered antibodies
  • Bispecific and multispecific constructs (where applicable to sponsor needs)

Key focus areas:

  • Analytical strategies that capture critical heterogeneity drivers (e.g., variants, fragmentation, aggregation)
  • Process conditions that manage stability and maintain functional integrity
  • Comparability planning for construct or process iterations

Recombinant Proteins

Sophia CDMO supports recombinant proteins and enzymes with development strategies designed around stability, activity, and manufacturability.

Services commonly include:

  • Expression and process optimization with manufacturability in mind
  • Purification approaches tailored to protein properties and impurity profiles
  • Potency strategy development (activity assays, binding assays, or other fit-for-purpose methods)
  • Formulation development to support stability during storage and administration
  • Stability and degradation pathway evaluation to reduce late-stage risk

Recombinant proteins often demand careful alignment between formulation, container closure, and analytical methods. Sophia CDMO integrates these workstreams to ensure data consistency and clear decision-making.

Fusion Proteins

Fusion proteins can introduce additional complexity in expression, folding, heterogeneity, and stability. Sophia CDMO supports fusion protein programs with a disciplined approach to characterization and control.

Typical focus areas include:

  • Product quality and variant profiling to define CQAs early
  • Process design to minimize misfolding, truncation, or unwanted variants
  • Formulation screening to manage aggregation risk and viscosity constraints
  • Comparability planning for construct refinements and scale transitions

Complex Biologics Requiring Advanced Characterization

Some biologics require extensive characterization due to complexity, mechanism, or sensitivity to manufacturing conditions. Sophia CDMO supports these programs by designing analytical plans that generate decision-grade insight, not just test results.

Examples of complexity drivers:

  • High propensity for aggregation or fragmentation
  • Multiple critical post-translational modifications
  • Narrow potency or purity windows
  • Stability challenges under real-world handling conditions

How we support these programs:

  • Risk-based analytical panels aligned to intended use
  • Stress studies to understand degradation pathways
  • Process and formulation adjustments driven by analytical evidence
  • Structured comparability packages for process or site changes

Development “Platforms” That Accelerate Execution

Sophia CDMO applies platform thinking where it improves speed and predictability, while tailoring execution to each molecule’s unique needs.

Phase-Appropriate Development Framework

We apply a staged approach that emphasizes rapid learning early and increasing rigor as programs mature.

  • Early phase: Fast iteration, fit-for-purpose methods, and pragmatic risk reduction
  • Mid phase: Process robustness, improved method performance, tighter control strategies
  • Late phase/commercial readiness: Validation-aligned approaches, comparability readiness, and lifecycle planning

This reduces both over-engineering early and rework late.

Integrated Process + Analytics Approach

We design upstream/downstream development in parallel with analytical development so the process is informed by product quality data from the start. This integration improves:

  • Speed of root-cause investigations
  • Comparability readiness
  • Control strategy clarity
  • Confidence during scale-up and tech transfer

Modalities by Program Stage

Preclinical and Early Clinical (IND/CTA-Enabling)

Sophia CDMO supports early programs that require fast timelines and clear data to support first-in-human dosing.

Typical outcomes:

  • A manufacturable process concept with early scalability considerations
  • A fit-for-purpose analytical package supporting release and stability
  • Initial formulation suitable for early clinical supply
  • Documentation packages that support regulatory submissions

Phase II / Phase III Expansion

As programs mature, Sophia CDMO supports:

  • Increased process robustness and tighter parameter control
  • Expanded characterization and stability data packages
  • Comparability strategies for scale changes or facility transitions
  • Readiness planning for PPQ and commercial supply strategies

Commercial Readiness and Lifecycle Support

For late-stage programs, Sophia CDMO emphasizes:

  • Documentation and validation-aligned planning
  • Supply reliability and quality system maturity
  • Continued process verification concepts (as applicable)
  • Change management planning and comparability readiness

Specialized Support for Biosimilar and Comparability Programs (Where Applicable)

Sophia CDMO supports comparability-focused programs where analytical depth, method performance, and controlled manufacturing execution are essential.

Support may include:

  • Analytical similarity strategy inputs (where applicable)
  • Method selection and development aligned to demonstrating comparability
  • Structured comparability study designs for process changes, scale transitions, or site transfers
  • Data narrative support for CMC documentation

We focus on generating data that is clearly interpretable, traceable, and aligned to the comparability questions regulators will ask.

Route of Administration and Product Considerations

Sophia CDMO supports biologics intended for common administration routes, with development and formulation considerations aligned to product needs.

Common considerations we address:

  • Stability requirements for refrigerated or frozen storage
  • Viscosity constraints for high-concentration products (where applicable)
  • Container compatibility and handling stress risks
  • Requirements for clinical packaging configurations and supply logistics (as applicable)

Where fill/finish is performed by qualified partners, Sophia CDMO provides technical coordination to maintain comparability alignment and documentation continuity.

How We Match the Right Platform to Your Program

Sophia CDMO typically begins with a structured assessment to determine the most efficient technical path:

  1. Molecule and modality review: format, known liabilities, potency approach, target profile
  2. Data gap assessment: analytical status, process maturity, material availability, stability knowledge
  3. Risk register and control strategy outline: what matters most, what can wait, what must be proven now
  4. Execution plan: experiments, deliverables, timeline, and decision gates

This approach ensures resources are focused on the highest-impact risks and the most time-sensitive deliverables.

Summary

Sophia CDMO supports a wide range of biologic platforms—mAbs, antibody-based therapeutics, recombinant proteins, fusion proteins, and complex biologics—through an integrated process, analytical, and quality-driven approach. We apply platform knowledge to accelerate early execution while tailoring strategies to each molecule’s unique profile, ensuring a practical path from development to scalable manufacturing.